在错配修复等位基因完整/微卫星稳定的转移性结直肠癌中优化免疫联合疗法

MGMT甲基化的pMMR mCRC病患者换用替莫唑胺诱导2个年底，然后重新组建伊匹木嘌呤/纳武利成之嘌呤对这种治疗展开了研究者，交果辨识重度预处理病患者的合理率为43%[18]。这项研究者是否选择了在重新组建病原体放射治疗之前较强良好疾病病理学交构上的病患者唯不确实。与烷基化剂一样，PARP可也可以一连串这种同上现型，目之前即将展开实验研究者。

TAM可导致病原体可抑制普遍性TME。虽然M1巨噬蛋白质一连串坏死，但M2同上现型愈来愈具病原体可抑制功用。一些载体药物，如瑞戈非尼；大伐替尼，可以降低M2的暗示，促进M1分化[19,20]。瑞戈非尼和纳武利成之嘌呤重新组建使用在日本线或或后线放射治疗的pMMR mCRC病患者之中辨识成活普遍性，在这种治疗难治普遍性环境之中，ORR为36%，mPFS为7.9个年底[21]。除1唯病患者外，所有有应答的病患者均患有pMMR mCRC，在这项1b期研究者之中辨识成合理普遍性回波。然而，在北美人群之中，这种一组并未辨识成合理普遍性，ORR为7%[22]。无肝转移的病患者只不过从这种一组之中获益最多，ORR为21%。此外，与瑞戈非尼相对于，在pMMR mCRC治疗难治普遍性环境之中，使用阿替利珠嘌呤和考比替尼（cobimetinib）的这种重新组建治疗并未辨识成合理普遍性[16]。乐伐替尼和托博利珠嘌呤的重新组建治疗即将展开3期研究者（NCT04776148）。

这些研究者包括了ICIs显然在pMMR mCRC之中合理的回波；然而，还能够愈来愈多的数据和一新放射治疗方法。

何为合理的病原体放射治疗一组？

目之前在临床实践之中，对于pMMR mCRC唯不合理的ICI重新组建放射治疗。然而，目之前有几项实验即将研究者基于pMMR mCRC临床之前病理学研究者的新一组。

多臂CheckMate-142研究者（NCT02060188）即将指标纳武利成之嘌呤重新组建伊匹木嘌呤、relatlimab（外用LAG3外用体）和Daratumab（CD38外用体）的功用。暗示CD38的骨髓外充质干蛋白质在pMMR-mCRC之中较强病原体可抑制功用，载体这些蛋白质可诱导对ICIs敏感的坏死恶普遍性。iSCORE研究者（NCT03867799）也在指标relatlimab和纳武利成之嘌呤在无治疗提议之中对经EGFR可放射治疗后健康状况令人满意的pMMR mCRC病患者的影响。这项研究者是基于的临床之前数据辨识，暴露于EGFR可后LAG3（可抑制普遍性T蛋白质蛋白）升至；而对其阻断显然会一连串病原体坏死同上现型[23]。

为何pMMR mCRC对ICI并未的病理学根基即将研究者之中，而即将研究者之中的ICI一组辨识成较强良好的药效。pMMR mCRC放射治疗的未来显然会将病原体治疗与其他系统化外用恶普遍性治疗辅以，但最佳一组仍不确实。

来源

（上下滑动可拍照）

1.André T, Shiu K-K, Kim TW, et al; KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218.

2.Shiu K-K, Andre T, Kim TW, et al. KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol. 2021;39(3_suppl):6.

3.Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779.

4.Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-2520.

5.O'Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848.

6.Chen EX, Jonker DJ, Kennecke HF, et al. CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). J Clin Oncol. 2019;37(4_suppl)481.

7.Shahda S, Noonan AM, Bekaii-Saab TS, et al. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. J Clin Oncol. 2017;35(15_suppl)3541.

8.Patel MR, Falchook GS, Hamada K, Makris L, Bendell JC. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heily pretreated microsatellite-stable metastatic colorectal cancer. Cancer Med. 2021;10(4):1183-1190.

9.Cremolini C, Rossini D, Antoniotti C, et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol. 2021;32(5):S1294-S1295.

10.Mettu NB, Twohy E, Ou F-S, et al. BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study. Ann Oncol. 2019;30(suppl_5):v203.

11.Grothey A, Tabernero J, Arnold D, et al. Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Ann Oncol. 2018;29(8):VIII714-VIII715.

12.Stein A, Binder M, Goekkurt E, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216). J Clin Oncol. 2020 Feb 1;38(4_suppl):96.

13.Martinelli E, Martini G, Famiglietti V, et al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA Oncol. 2021;7(10):1529-1535.

14.Gomez-Roca C, Yanez E, Im S-A, et al. LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.. J Clin Oncol. 2021 Jan 22;39(3_suppl):94–94.

15.Cousin S, Bellera CA, Guégan JP, et al. REGOMUNE: A phase II study of regorafenib plus elumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.. J Clin Oncol. 2020 May 25;38(15_suppl):4019–4019.

16.Eng C, Kim TW, Bendell J, et al; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849-861.

17.Segal NH, Cercek A, Ku G, et al. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. Clin Cancer Res. 2021;27(8):2200-2208.

18.Pietrantonio F, Morano F, Lonardi S, et al. 3830 MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC). Ann Oncol. 2021;32(S5):S530-S531.

19.Ou D-L, Chen C-W, Hsu C-L, et al. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages. J Immunother Cancer. 2021;9(3):e001657.

20.Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513.

21.Fukuoka S, Hara H, Takahashi N, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053-2061.

22.Fakih M, Ragh KPS, Chang DZ, et al. Single-arm, phase II study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC). J Clin Oncol. 2021;39(15_suppl):3560.

23.Woolston A, Khan K, Spain G, et al. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell. 2019;36(1):35-50.e9.

。

太原医院性病
南昌医院地址
贵阳看癫痫哪家医院专业
消痔软膏和马应龙痔疮栓区别
早上手指僵硬怎么办
孕妇便秘用什么药
非酒精性脂肪肝怎么治疗
常乐康和亿活哪个好